<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38830512</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6825</ISSN><JournalIssue CitedMedium="Internet"><Volume>154</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of allergy and clinical immunology</Title><ISOAbbreviation>J Allergy Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Whole blood transcriptome in long-COVID patients reveals association with lung function and immune response.</ArticleTitle><Pagination><StartPage>807</StartPage><EndPage>818</EndPage><MedlinePgn>807-818</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2024.04.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0091-6749(24)00566-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Months after infection with severe acute respiratory syndrome coronavirus 2, at least 10% of patients still experience complaints. Long-COVID (coronavirus disease 2019) is a heterogeneous disease, and clustering efforts revealed multiple phenotypes on a clinical level. However, the molecular pathways underlying long-COVID phenotypes are still poorly understood.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We sought to cluster patients according to their blood transcriptomes and uncover the pathways underlying their disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Blood was collected from 77 patients with long-COVID from the Precision Medicine for more Oxygen (P4O2) COVID-19 study. Unsupervised hierarchical clustering was performed on the whole blood transcriptome. These clusters were analyzed for differences in clinical features, pulmonary function tests, and gene ontology term enrichment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clustering revealed 2 distinct clusters on a transcriptome level. Compared with cluster 2 (n&#xa0;= 65), patients in cluster 1 (n&#xa0;= 12) showed a higher rate of preexisting cardiovascular disease (58% vs 22%), higher prevalence of gastrointestinal symptoms (58% vs 29%), shorter hospital duration during severe acute respiratory syndrome coronavirus 2 infection (median, 3 vs 8 days), lower FEV<sub>1</sub>/forced vital capacity (72% vs 81%), and lower diffusion capacity of the lung for carbon monoxide (68% vs 85% predicted). Gene ontology term enrichment analysis revealed upregulation of genes involved in the antiviral innate immune response in cluster 1, whereas genes involved with the adaptive immune response were upregulated in cluster 2.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides a start in uncovering the pathophysiological mechanisms underlying long-COVID. Further research is required to unravel why the immune response is different in these clusters, and to identify potential therapeutic targets to create an optimized treatment or monitoring strategy for the individual long-COVID patient.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blankestijn</LastName><ForeName>Jelle M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands. Electronic address: j.m.blankestijn@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baalbaki</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazdar</LastName><ForeName>Somayeh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekers</LastName><ForeName>In&#xe9;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Health, Ortec B.V., Zoetermeer, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beijers</LastName><ForeName>Rosanne J H C G</ForeName><Initials>RJHCG</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Bergh</LastName><ForeName>Joop P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands; Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloemsma</LastName><ForeName>Lizan D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornelissen</LastName><ForeName>Merel E B</ForeName><Initials>MEB</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dekker</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Experimental Immunology (EXIM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duitman</LastName><ForeName>Jan Willem</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Experimental Immunology (EXIM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houweling</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>John J L</ForeName><Initials>JJL</Initials><AffiliationInfo><Affiliation>Department of Health, Ortec B.V., Zoetermeer, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Ivo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Spaarne Hospital, Hoofddorp, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linders</LastName><ForeName>Paulien M A</ForeName><Initials>PMA</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noij</LastName><ForeName>Lieke C E</ForeName><Initials>LCE</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nossent</LastName><ForeName>Esther J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Pol</LastName><ForeName>Marianne A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sondermeijer</LastName><ForeName>Brigitte M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Spaarne Hospital, Hoofddorp, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geelhoed</LastName><ForeName>J J Miranda</ForeName><Initials>JJM</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Leiden University Medical Center (LUMC), Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weersink</LastName><ForeName>Els J M</ForeName><Initials>EJM</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golebski</LastName><ForeName>Korneliusz</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Aziz</LastName><ForeName>Mahmoud I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands; Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maitland-van der Zee</LastName><ForeName>Anke H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands; Department of Pediatric Respiratory Medicine, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>P4O2 Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Allergy Clin Immunol</MedlineTA><NlmUniqueID>1275002</NlmUniqueID><ISSNLinking>0091-6749</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DLCO</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">lung function</Keyword><Keyword MajorTopicYN="N">phenotyping</Keyword><Keyword MajorTopicYN="N">transcriptome</Keyword></KeywordList><CoiStatement>Disclosure statement Disclosure of potential conflict of interest: K. Golebski received funds paid to the institution from the ZonMW grant long COVID; received funds from GlaxoSmithKline (GSK), ALK, and STIMAG; and received consulting fees from GSK. J. W. Duitman has received research funding from Boehringer Ingelheim and Abbvie. M. I. Abdel-Aziz was funded by a full PhD scholarship from the Ministry of Higher Education of the Arab Republic of Egypt during the conduct of the study and received a grant from Stichting Astma Bestrijding. A. H. Maitland-van der Zee received money paid to the institution from the ERANET Systems Medicine and ZonMW grant, another ZonMW grant for COVID-19 research, the Stichting TAAI research grant, the EUROSTARS research grant COPDetect, an unrestricted research grant from Boehringer Ingelheim and GSK, an unrestricted research grant from the Vertex Innovation Award, and the Innovative Health Initiative 3TR research grant; is the (unpaid) chair of the DSMB SOS BPD study; and was the president of the federation of innovative drug research in the Netherlands (FIGON). The rest of the authors declare that they have no relevant conflicts of interest. Data availability: The data are available in the GEO omnibus under accession GSE267625. Also accessible with the link https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267625.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>7</Day><Hour>14</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>4</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38830512</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2024.04.032</ArticleId><ArticleId IdType="pii">S0091-6749(24)00566-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>